Skip Navigation LinksHome > January/February 2005 - Volume 28 - Issue 1 > Effect of Serum and Antioxidants on the Immunogenicity of Pr...
Journal of Immunotherapy:
Basic Studies

Effect of Serum and Antioxidants on the Immunogenicity of Protein Kinase C-Activated Chronic Lymphocytic Leukemia Cells

Hammond, Caitlin*†; Shi, Yonghong*; Mena, Jenny*; Tomic, Jelena*†; Cervi, David*†; He, Liwei‡; Millar, Amanda E.‡; DeBenedette, Mark‡; Schuh, Andre C.†‡§; Baryza, Jeremy L.; Wender, Paul A.; Radvanyi, Laszlo‡; Spaner, David E.*†¶**

Collapse Box

Abstract

Since the intrinsically poor immunogenicity of chronic lymphocytic leukemia (CLL) cells might be a key factor in allowing them to avoid immune control mechanisms, the development of methods to enhance CLL cell immunogenicity might lead to improved disease control. The ability of CLL cells to stimulate T cells was increased significantly by the protein kinase C (PKC) agonist phorbol myristic acetate (PMA). However, under serum-free conditions, PMA-activated CLL cells died within 48 hours. Antioxidants, such as 2-mercaptoethanol (2-ME), or fetal calf serum could prevent the death of these cells but caused them to enter distinct states of differentiation. In the presence of 2-ME, PMA-activated CLL cells extended dendritic-like protrusions and exhibited increased T-cell stimulatory capacity. In the presence of serum, PMA-activated CLL cells developed fewer dendrites, made less IL-10 and more IL-12 p40 mRNA transcripts, and showed an increased capacity to induce IFN-γ production by T cells. The effects of serum on the promotion of type 1 immune responses by phorbol ester-activated CLL cells were dominant and correlated with activation of the NF-κB signaling pathway. Other PKC agonists, such as Bryostatin-1 and a synthetic Bryostatin analog (Picolog), had similar effects on CLL cells. The observation that CLL cells can acquire features of dendritic cells that promote type 1 immunity may find clinical application in immunotherapeutic strategies for this disease.

© 2005 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Call for Papers

Journal of Immunotherapy has issued a call for papers. With an impact factor of 3.203, JOI is a leading journal in the fields of immunology and oncology.

For manuscript submission, go to: http://www.editorialmanager.com/jit/

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JOFIonline

For additional oncology content, visit LWW Oncology Journals on Facebook.